These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 954239)

  • 1. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
    Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
    Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of hemodialysis hemosiderosis with desferrioxamine.
    Rembold CM; Krumlovsky FA; Roxe DM; Fitzsimmons E; del Greco F
    Trans Am Soc Artif Intern Organs; 1982; 28():621-6. PubMed ID: 7164314
    [No Abstract]   [Full Text] [Related]  

  • 9. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA; Campbell F; Savory J; Chevalier RL
    Int J Pediatr Nephrol; 1987; 8(1):21-4. PubMed ID: 3583552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
    el-Gholmy A; Khalifa AS; Rahman YA; el-Bagoury I
    J Trop Med Hyg; 1969 Jan; 72(1):22-6. PubMed ID: 5773810
    [No Abstract]   [Full Text] [Related]  

  • 11. Desferrioxamine in the management of dialysis hemosiderosis.
    Krumlovsky FA
    Int J Artif Organs; 1982 Jul; 5(4):223-5. PubMed ID: 7118282
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement of anaemia with desferrioxamine in haemodialysis patients.
    Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
    Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P
    Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537
    [No Abstract]   [Full Text] [Related]  

  • 14. Transfusion hemosiderosis. Report of a case treated with desferrioxamine-B.
    Kaung DT
    J Iowa Med Soc; 1965 Jun; 55(6):312-6. PubMed ID: 5835475
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B.
    Bayraktar Y; Saglam F; Temizer A; Uzunalimodlu B; van Thiel DH
    Hepatogastroenterology; 1998; 45(24):2322-7. PubMed ID: 9951916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of hemosiderosis with deferoxamine].
    Strohmeyer G; Stremmel W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1669-70. PubMed ID: 6489179
    [No Abstract]   [Full Text] [Related]  

  • 17. [Possibilities and limitation of desferrioxamine treatment of transfusion hypersiderosis in children].
    Orsini A; Passeron P; Perrimond H; Pierron H
    Pediatrie; 1968; 23(5):588-9. PubMed ID: 5675452
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Deferoxamine B treatment of hemosiderosis in the anephric patient undergoing hemodialysis].
    Ceriati F; Cavicchioni C; Marino IR; Pomponi M
    Chir Patol Sper; 1981 Feb; 29(1):14-9. PubMed ID: 7344858
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J; Stobbe H
    Z Gesamte Inn Med; 1984 Apr; 39(8):167-9. PubMed ID: 6730593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.